Latest Healthcare It News

Epsilon Healthcare has launched a $1 million loan note issue aimed at supporting its working capital and diversification efforts, with a 10% interest rate and potential share conversion.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

Genetic Technologies Limited has announced significant leadership changes, appointing Michael Walker as Executive Chairman and Managing Director, alongside new executive and board members.

Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.

Rhythm Biosciences’ subsidiary Genetype has landed a pivotal 12-month contract with the University of Melbourne to provide advanced breast cancer risk assessments, marking a significant step in personalised cancer screening.

Paradigm Biopharmaceuticals has secured centralised US ethics approval for its pivotal Phase 3 trial of injectable pentosan polysulfate sodium (iPPS) targeting moderate to severe knee osteoarthritis, setting the stage for patient enrolment in Q3 2025.

MedAdvisor Limited has successfully closed its Share Purchase Plan, raising $2.668 million-exceeding its $2 million target-and plans an upcoming shareholder meeting to approve director share issuances.

Amplia Therapeutics reports a significant milestone in its ACCENT trial, with 15 confirmed partial responses indicating that narmafotinib combined with chemotherapy outperforms chemotherapy alone in advanced pancreatic cancer.

Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.

Mayne Pharma has addressed a sharp share price decline following the public release of an FDA Untitled Letter, confirming no undisclosed material information and reaffirming compliance with ASX rules.

Genetic Technologies Limited has officially exited external administration following the effectuation of a Deed of Company Arrangement, marking a significant shift in its corporate governance and creditor relations.

EBR Systems has won FDA approval for its pioneering leadless WiSE CRT System, setting the stage for a phased US commercial rollout. The company also secured key Medicare reimbursement pathways and expanded manufacturing capacity, though financial sustainability remains a concern.